菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Newsletter: November 2021

Regulatory Updates

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility Read More

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date Read More

 

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate Read More

 

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility Read More

 

WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA) Read More


Resources

The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. View this Podcast

For more information on our Quality track record, please click this infographic.


Partner News

WuXi Biologics Congratulates Amicus on U.S. FDA’s Acceptance of its Filing for AT-GAA for the Treatment of Pompe Disease Read More